Paratek Pharmaceuticals to Report Fourth Quarter 2015 Financial Results on February 23, 2016

BOSTON, Feb. 16, 2016 -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry, announced today that it will host a conference call and live audio webcast on Tuesday, February 23, 2016, at 8:30 AM ET to report fourth quarter 2015 financial results and provide a corporate update.

The live webcast can be accessed under "Events and Presentations" in the Investor Relations section of the Company's website at www.paratekpharma.com.

Domestic investors wishing to participate in the call should dial 888-430-8705 using conference ID 8443972. International investors should dial 719-457-2627 using conference ID 8443972. Investors can also access the call at http://public.viavid.com/index.php?id=118299.

Replays of the call will be available through March 8, 2016. Domestic investors can access the replay by dialing 877-870-5176. International investors can access the replay by dialing 719-325-2435. The PIN code to access the replay is 8443972.

About Paratek

Paratek Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon its expertise in novel tetracycline chemistry. Paratek's lead product candidate, omadacycline, is the first in a new class of tetracyclines known as aminomethylcyclines, with broad-spectrum activity against Gram-positive, Gram-negative and atypical bacteria. Paratek initiated a Phase 3 registration study in ABSSSI in June 2015 to determine the efficacy and safety of omadacycline compared to linezolid. Top-line data from this study will be available in mid-2016.  A Phase 3 registration study for CABP with omadacycline was initiated in November 2015.

Omadacycline is a new once-daily oral and IV, well-tolerated broad-spectrum antibiotic being developed for use as empiric monotherapy for patients suffering from serious community-acquired bacterial infections, such as acute bacterial skin and skin structure infections, community acquired bacterial pneumonia, urinary tract infections, and other community-acquired bacterial infections, particularly when antibiotic resistance is of concern to prescribing physicians.

Paratek's second Phase 3 product candidate, sarecycline, is a new once-daily oral tetracycline-derived compound for the potential treatment of acne and rosacea in the community setting. Sarecycline is designed to be a well-tolerated, once-daily, oral, narrow spectrum antibiotic with anti-inflammatory properties. Allergan owns the U.S. rights for the development and commercialization of sarecycline. Paratek retains all ex-U.S. rights. Two identical Phase 3 registration studies were initiated by Allergan in December 2014 for sarecycline for the treatment of moderate to severe acne vulgaris.

For more information, visit www.paratekpharma.com.

CONTACTS:

Media Relations:
Michael Lampe
(484) 575-5040
[email protected]

Investor Relations:
Hans Vitzthum
LifeSci Advisors, LLC.
212-915-2568